UPDATE ON GAVI. Julian Lob-Levyt. Global Immunisation Meeting New York, February 2009

Transcription

1 UPDATE ON GAVI Julian Lob-Levyt

2 The GAVI Alliance Board structure GAVI Alliance Informal, not a legal entity Partner representatives Public sector expertise (plus vaccine industry) Programmatic oversight and policy development Responsible for approving country programmes GAVI Fund A legal entity Individual volunteers Private sector expertise Financial oversight (investment, accounting, auditing) Responsible for approving financing for country programmes 1

3 Positive outcomes for implementing countries Countries are better represented on both the Board and its committees. The Programme & Policy Committee will bring country perspectives to the forefront of all policy decisions. The partnership does not change. 2

4 GAVI support approvals, end

5 Immunisation coverage with DTP3, hepatitis B and Hib vaccines in GAVI-supported countries, Source/credits: WHO-UNICEF coverage estimates for , as of August 2008; WHO-ICE T coverage projections for , as of September

6 Reaching the hard to reach 5

7 Close to US$ 4 billion approved for country programmes through

8 Towards MDG 4 Projected expenditure, Estimates as at January 2009 * HPV, JE vaccines, rubella and typhoid ** Hib, hepb (tetra/monovalent), yellow fever, measles second dose Microsoft Office cel Binary Workshe

9 Country co-financing Boosting sustainability and country ownership of immunisation programmes. Compulsory for some countries from Well received: most countries fulfilled commitments. Some paid more and a few struggle. Country response to the policy show that vaccines are priority. Rasoka Thor/UNICEF Cambodia

10 Transparency & Accountability Policy rationale Increase in GAVI cash support: projected to be over $200m in Need to increase financial assurances of country programme implementation. Christine Nesbit/GAVI Alliance 9

11 Transparency & Accountability Policy implementation Began on 1 January 2009 and includes: Strengthen financial management sections in all new proposals and annual progress reports; Involve financial management experts on the Independent Review Committee; Develop an early warning system a modelling tool that allows GAVI to identify risks pre-emptively; Conduct financial management assessment (FMA). 10

12 Strengthening and aligning reviews APR (Annual progress report) 15 May 2009 submission deadline 15 May 1 September 11

13 Measuring impact Strong need for valid, reliable and useful measures of delivery and performance of GAVI support. GAVI partner concern: current data insufficient. KEY ACTIONS taken to address measurement challenge. 12

14 Accelerated Vaccines Introduction: The Plan Assist countries make decisions on introduction of pneumo & rota vaccines. Develop platform for introduction of other new vaccines. Target of 42 pneumo and 44 rota introductions by Detailed work-plan for 2009, with partners & AVI - TAC* roles mapped. * TAC = Technical Advisory Consortium (merged ADIPs & Hib initiative)

15 Other key issues Vaccine Investment Strategy currently developed: Board agreed focus on HPV, Rubella, Japanese Encephalitis and Typhoid (subject to finance). Future of service / systems components from 2010 (HSS and CSO evaluations and ISS future) Technical support: quality, availability, sustainability and transparency Eligibility criteria 14

16 Way forward Keep GAVI Alliance being accountable and transparent. International Health Partnership (IHP+) a milestone in the history of global health programming and financing. GAVI Alliance partners: foster the continued collaboration for in country activities. Regional Working Groups: strengthen the composition HSS & Immunisation) and the function to better support implementation of GAVI policies. Strengthening civil society organisation involvement and representation. Manage the impact of the international financial crisis. 15

17 16

18 Thank you 17